Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous telavancin versus vancomycin for complicated gram-positive skin and skin structure infections
2004-002914-12Phase 3Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Feb 2005
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in skin and soft tissue infections (SSTIs) and Staphylococcus aureus infection comparing Telavancin with Vancomycin (2 arms). Primary endpoint: Clinical response at Test-of-Cure. Started Feb 2005; status: completed.
02
Drugs
telavancinvancomycin
03
Conditions
skin and soft tissue infections (SSTIs)Staphylococcus aureus infection
Beyond the preview
Go deeper on 2004-002914-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002914-12.